| Name | Eflornithine hydrochloride hydrate |
| Description | Eflornithine hydrochloride hydrate (DFMO hydrochloride hydrate) is a specific and irreversible inhibitor of the ornithine decarboxylase (ODC). Eflornithine hydrochloride hydrate has antitumor activity and has also been used in the hirsutism Eflornithine hydrochloride hydrate has antitumor activity and is also used in the treatment of hirsutism. |
| Cell Research | BY2 cells are treated with or without cryptogein in the presence or absence of DFMO(Difluoromethylornithine) and monitered the effect of chemicals on cell growth. (Only for Reference) |
| In vitro | When cultured cells are treated with α-difluoromethyl-Orn, an inhibitor of polyamine biosynthesis, production of hydrogen peroxide is suppressed and programmed cell death did not occur[1]. |
| In vivo | Eflornithine stands as the only novel compound registered for human African trypanosomiasis treatment in the past five decades, primarily serving as an alternative for cases resistant to melarsoprol involving Trypanosoma brucei gambiense. Additionally, a 15% eflornithine cream demonstrates efficacy superior to placebo in diminishing excessive, unwanted facial hair growth in patients, with 58% of individuals treated with eflornithine observing at least some improvement in facial hirsutism after 24 weeks, compared to 34% of those receiving placebo. Furthermore, the inhibitory effect on hair growth by eflornithine cream is significantly amplified when applied to mouse skin previously treated with microneedles. In hypertensive rats with coarctation, eflornithine treatment normalizes contractile responses to KCI and norepinephrine, and enhances relaxations to acetylcholine within 14 days, indicating its broader pharmacological utility. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 2.77 mg/mL (11.71 mM), Sonication is recommended.
H2O : 83.33 mg/mL (352.14 mM), Sonication is recommended.
|
| Keywords | α-difluoromethylornithine hydrochloride Hydrate | α-difluoromethylornithine hydrochloride | RMI-71782 hydrochloride Hydrate | RMI-71782 hydrochloride | Parasite | MDL-71782 hydrochloride Hydrate | MDL-71782 hydrochloride | Inhibitor | inhibit | Eflornithine hydrochloride hydrate | Eflornithine hydrochloride Hydrate | Eflornithine Hydrochloride | Difluoromethylornithine hydrochloride Hydrate | DFMO hydrochloride Hydrate | DFMO hydrochloride | Decarboxylase | a-difluoromethylornithine hydrochloride Hydrate |
| Inhibitors Related | Picaridin | Flubendazole | Kojic acid | Urethane | Hydroxychloroquine | Metronidazole | Nitazoxanide | 2-Amino-2-methyl-1-propanol | Doxycycline | Fenpyroximate | Coumaran | Cloxiquine |
| Related Compound Libraries | Highly Selective Inhibitor Library | Anti-Parasitic Compound Library | Failed Clinical Trials Compound Library | Bioactive Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Cancer Approved Drug Library | FDA-Approved Drug Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |
United States
